Quantcast

Latest Metaplasia Stories

2010-04-12 11:13:05

Atrophic gastritis and intestinal metaplasia are two important precursory lesions in the process of intestinal type gastric cancer.

2010-02-10 09:07:49

Gastric cancer remains a significant problem globally.

2009-06-03 12:00:00

Radiofrequency ablation is durable after 2 years, compares favorably with endoscopic resection for advanced disease, and reduces the risk for cancer progression SUNNYVALE, Calif., June 3 /PRNewswire/ -- Results from a number of clinical trials were presented during the Digestive Disease Week (DDW) in Chicago this week, revealing new outcomes data related to endoscopic radiofrequency ablation using the HALO ablation system for eradicating a pre-cancerous esophageal condition known as...

2009-06-01 17:00:00

Large multi-center trial conducted in a community practice setting demonstrates comparable outcomes as trials conducted in predominantly tertiary academic centers SUNNYVALE, Calif., June 1 /PRNewswire/ -- Clinical trial results presented at the Digestive Disease Week in Chicago today reveal that endoscopic radiofrequency ablation performed in a community practice setting is safe and effective for eradicating a pre-cancerous esophageal condition known as Barrett's esophagus.

2009-05-15 08:39:07

In a review of more than 2,000 patients coded for Barrett's esophagus, electronic diagnosis overestimated the prevalence of the disease according to researchers in California.

2008-10-01 12:00:07

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- SpectraScience, Inc.

2008-09-16 15:00:11

SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- SpectraScience, Inc.

2008-07-21 00:00:15

SUNNYVALE, Calif., July 21 /PRNewswire/ -- BARRX Medical, Inc. today announced that 98.4 percent of patients having a precancerous condition of their esophagus called Barrett's esophagus were free of the disease 2.5 years after non-surgical, endoscopic treatment with the HALO ablation system.

2007-05-20 21:00:19

SUNNYVALE, Calif., May 20 /PRNewswire/ -- BARRX Medical, Inc. today announced that 98.4% of patients with Barrett's esophagus treated with the HALO Ablation System have no residual Barrett's esophagus tissue after a follow up period of more than two and a half years.